Held10 days
Entry$3.93Close$7.74PnL+97.20%
67%
confidence
Angle A negative AdCom may have washed out CAPR before the still-open Aug. 22 PDUFA decision.
CAPR has collapsed after FDA briefing concerns and a 3-9 AdCom vote, but the forward setup is still the August 22 PDUFA for Deramiocel rather than the already-fired panel reaction [#28, #32, #38]. The bull case is that FDA could still approve or conditionally approve on a narrower DMD label, with supporters pointing to PUL/LVEF arguments, SAP process defenses, and published 54% slowing of upper-limb decline in The Lancet [#2, #17, #20, #21, #24]. That makes the trade a high-risk regulatory mean reversion: the stock has repriced for failure, while the final agency decision remains open.
AI Status: CAPR closed for a +97.2% gain after ten days, exiting on our exit signal after peaking near +109% amid post-AdCom volatility ahead of the Aug. 22 PDUFA.
The position entered at $3.92 and exited near $7.74, realizing a 97.2% gain over ten trading days while retaining most of the move from a +108.9% peak. Drawdown from entry stayed modest at about 5.9%, and the close came roughly 5.6% below the high-water mark as the FDA briefing and AdCom vote drove a sharp repricing. At exit, daily RSI sat near 38.5 with MACD histogram turning positive, even as price remained below the 20-day EMA in a very strong downtrend.
